Efforts towards inhibiting mTOR with rapalogs (including rapamycin and analogs) have been pursued in cancer therapeutics; however, the exclusive utilization of rapalogs displayed suboptimal efficacy [199]. The gene discussed is MTOR; the disease is cancer.